Amicus is focused on the following four key strategic priorities in 2024: Delivering double-digit Galafold revenue growth — 11%-16% at CER; Ensuring the successful global launches of Pombiliti + Opfolda; Advancing ongoing studies to support medical and scientific leadership in Fabry and Pompe diseases; Achieving full year non-GAAP profitability.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on FOLD:
- Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
- ‘Time to Pull the Trigger,’ Says Morgan Stanley About These 2 Healthcare Stocks
- Amicus upgraded to Overweight from Equal Weight at Morgan Stanley
- Amicus executive chairman John Crowley to step down
- Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO
